In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
- 1 April 1997
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (4) , 863-865
- https://doi.org/10.1128/aac.41.4.863
Abstract
The in vitro activities of LY-303366, a new semisynthetic echinocandin, and comparators amphotericin B, 5-fluorocytosine, fluconazole, and ketoconazole against 205 systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species were determined. LY-303366 had MICs of < or = 0.32 microg/ml for all Candida albicans (n = 99), Candida glabrata (n = 18), and Candida tropicalis (n = 10) isolates tested. LY-303366 was also active against Aspergillus species (minimum effective concentration at which 90% of the isolates are inhibited, 0.02 microg/ml) (n = 20), was less active against Candida parapsilosis (MIC at which 90% of the isolates are inhibited [MIC90], 5.12 microg/ml) (n = 10), and was inactive against C. neoformans (MIC90, >10.24 microg/ml) (n = 15) and B. dermatitidis (MIC90, 16 microg/ml) (n = 29).Keywords
This publication has 5 references indexed in Scilit:
- Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthaseAntimicrobial Agents and Chemotherapy, 1994
- Human Mycoses: Drugs and Targets for Emerging PathogensScience, 1994
- Mechanisms and clinical impact of antifungal drug resistanceMedical Mycology, 1994
- Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989The American Journal of Medicine, 1991
- In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) againstAspergillus andCandida speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990